Protalix Q2 2026: YTD revenue $53.6M, net income $22.1M; Elfabrio patent extended to 2035

Protalix BioTherapeutics, Inc.

Q2 goods revenue $19.8M, up $4.4M YoY on Elfabrio sales; YTD total revenue $53.6M vs $25.8M in 2025
Year-to-date net income $22.1M, achieving profitability; cash and short-term deposits $40.7M at June 30, 2026
FY2026 revenue guidance reaffirmed at $78-83M incl. $25M Chiesi milestone; Elfabrio $33-35M, Elelyso $20-23M
USPTO extended Elfabrio US patent to Nov 17, 2035 (May 4, 2026); South Korea orphan drug designation + MA granted May 2026
PRX-115 Phase 2 RELEASE enrollment ongoing; top-line results expected H2 2027; USPTO issued uricase patent July 7, 2026

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.